EQS-News: ABIVAX / Key word (s): Personnel Abivax Announces a Change to the Composition of its Board of Directors 23.12.2024 / 22:05 CET/CEST The issuer is solely responsible for the content of ...

Abivax Announces a Change to the Composition of its Board of DirectorsPARIS, France, December 23, 2024, 10:05 PM CEST – Abivax SA (Euronext Paris ...

For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months ...

In a year of pivotal gastroenterology research, these 10 articles were in a class of their own, according to Dr David Johnson ...

For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months ...

Researchers in Michael Sigals lab at the Max Delbruck Center and Charite - Universitatsmedizin Berlin have discovered the ...

Upadacitinib may offer superior disease management than tofacitinib for patients with ulcerative colitis. Learn more.

It's long been considered a disease for older people but research shows bowel cancer rates in young people are rising. And ...

Managing inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, may soon become more advanced and ...

The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...

The company announced that it is looking to move to Phase II after its ulcerative colitis treatment saw success over placebo.

Topline Clinical Data Demonstrates Activity of SOR102 Across Multiple Clinical Endpoints Supporting Advancement to Phase 2 Development SALT LAKE CITY, UT, USA I 19, 2024 I Sorriso Pharmaceuticals, a ...